Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000875362 | SCV001017676 | likely benign | Nemaline myopathy 2 | 2024-07-17 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001508089 | SCV001714010 | uncertain significance | not provided | 2020-11-02 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV001508089 | SCV003811614 | likely benign | not provided | 2023-04-12 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001508089 | SCV004169156 | uncertain significance | not provided | 2023-05-11 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published in association with NEB-related nemaline myopathy to our knowledge; This variant is associated with the following publications: (PMID: 28719003, 26740555) |
Ambry Genetics | RCV005372477 | SCV006039729 | uncertain significance | Inborn genetic diseases | 2025-01-18 | criteria provided, single submitter | clinical testing | The c.8063A>G (p.H2688R) alteration is located in exon 58 (coding exon 56) of the NEB gene. This alteration results from a A to G substitution at nucleotide position 8063, causing the histidine (H) at amino acid position 2688 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV000875362 | SCV001457001 | uncertain significance | Nemaline myopathy 2 | 2020-01-10 | no assertion criteria provided | clinical testing |